Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a place as treatment for a subset of these patients.
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
